Summary: It is well known that some pathogenic cells have enhanced glycolysis, the regulatory network leading to increased glycolysis are not well characterized. Here, we show that pathogenic T H 17 cells specifically upregulate glycolytic pathway genes compared to homeostatic T H 17 cells. Bioenergetic assay and metabolomics analyses indicate that pathogenic T H 17 cells are highly glycolytic compared to nonpathogenic T H 17 cells. Chromatin landscape analyses demonstrate T H 17 cells in vivo show distinct chromatin states, and pathogenic T H 17 cells show enhanced chromatin accessibility at glycolytic genes with NF-kB binding sites. Mechanistic studies reveal that TGF-β1 signaling induces T H 17 cell chromatin remodeling and represses c-Rel-mediated glycolysis. A miR-21-Peli1 -c-Rel loop was further identified to be essential for glycolysis of pathogenic T H 17 cells. These findings extend our understanding of the regulation T H 17 cell glycolysis in vivo and provide insights for future therapeutic intervention to T H 17 cell mediated autoimmune diseases.